Replimune Group, Inc.

Stocks

REPL

US76029N1063

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
17.61 ^USD	+1.27%		+53.66%	+81.17%

10-29	Replimune Group, Inc., Q2 2027 Earnings Call, Oct 28, 2026
10-28	Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI

Transcript : Replimune Group, Inc. - Shareholder/Analyst Call

Published on 08/07/2026 at 03:52 pm +03

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the TUDRIQEV FDA Accelerated Approval Call. [Operator Instructions] Please be advised that today's

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Replimune Group, Inc.

10-29	Replimune Group, Inc., Q2 2027 Earnings Call, Oct 28, 2026
10-28	Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
10-28	Replimune Shares Fall Even After Company Posts Narrower Fiscal Q2 Net Loss	MT
10-28	Earnings Flash (REPL) Replimune Posts Fiscal Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.71 Loss	MT
10-01	Replimune Receives Approval to Launch Tudriqev in the US for Melanoma	MT
10-01	Replimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced Melanoma	CI
09-15	Replimune Group, Inc. - Shareholder/Analyst Call
08-19	Trump picks White House adviser Heidi Overton to run FDA, source says	RE
08-14	Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-14	Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026	CI
08-14	Replimune Fiscal Q1 Net Loss Narrows	MT
08-14	Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss	MT
08-10	Replimune Prices $150 Million Offering	MT
08-07	Replimune Group, Inc. - Shareholder/Analyst Call
08-07	Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12	MT